2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethanamine | 1023451-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethanamine
• 英文别名: 2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethylamine；2-(5-Chloro-1-methylimidazol-4-yl)ethanamine
• CAS: 1023451-28-6
• 化学式: C₆H₁₀ClN₃
• 分子量: 159.618
• InChiKey: UQSZTRPNDUYJRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 、 2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethanamine 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以75%的产率得到
  参考文献：
  名称：

  SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors

  摘要：

  The SAR of PXR transactivation by 3-(benzimidazol-2-yl)-pyridine-2-one based ATP competitive inhibitors of Insulin-like Growth Factor 1 Receptor kinase (IGF-1R) is discussed. Compounds without PXR transactivation, with in vivo antitumor activity, reduced protein binding and improved oral exposure are presented. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.087

文献信息

• [EN] BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS<br/>[FR] COMPOSÉS BIARYLES UTILES EN TANT QU'IMMUNOMODULATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018044963A1

  公开（公告）日：2018-03-08

  The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

  本公开涉及通常用作免疫调节剂的化合物。本文提供了包含这些化合物的组合物，以及它们的使用方法。该公开进一步涉及包含至少一种根据本公开的化合物的药物组合物，用于治疗各种疾病，包括癌症和传染病。
• Compounds useful as immunomodulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10144706B2

  公开（公告）日：2018-12-04

  The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

  本公开内容一般涉及可用作免疫调节剂的化合物。本文提供了化合物、包含此类化合物的组合物及其使用方法。本公开进一步涉及包含至少一种根据本公开的化合物的药物组合物，这些组合物可用于治疗各种疾病，包括癌症和传染性疾病。
• EP3507284A1
  申请人：——

  公开号：EP3507284A1

  公开（公告）日：2019-07-10
• BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3507284B1

  公开（公告）日：2022-05-25
• COMPOUNDS USEFUL AS IMMUNOMODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20180057455A1

  公开（公告）日：2018-03-01

  The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.